Literature DB >> 8023773

Comparison of primary angioplasty versus thrombolytic therapy for acute myocardial infarction. Alabama Registry of Myocardial Ischemia Investigators.

W J Rogers1, L S Dean, P B Moore, K J Wool, S L Burgard, E L Bradley.   

Abstract

To determine the relative merits of primary percutaneous transluminal coronary angioplasty (PTCA) and intravenous thrombolytic therapy for acute myocardial infarction, 12 tertiary care hospitals entered patients who had > or = 30 minutes of chest pain and were admitted to a cardiac intensive care unit within 12 hours of symptom onset into a prospective registry. Of 1,170 such patients, 118 (10%) underwent primary PTCA and 230 (19%) received intravenous thrombolytic therapy within 6 hours of registry hospital admission (144 at the registry hospital and 86 prior to arrival at the registry hospital). Baseline demographic characteristics of PTCA and thrombolytic subgroups were remarkably similar. The interval from initial evaluation at the registry hospital to treatment was shorter with intravenous thrombolytic therapy than with primary PTCA (64 vs 104 minutes, p < 0.001), as was the interval from pain onset to treatment (184 vs 252 minutes, p < 0.001). Among the 230 thrombolytic patients, coronary arteriography and PTCA were performed within the first 24 hours in 44% and 18%, respectively, and during the entire hospitalization in 90% and 49%, respectively. During hospitalization, blood was transfused in 16% of the 230 thrombolytic patients versus 5.9% of the 118 PTCA patients (p < 0.001). Otherwise, adverse events during the initial hospitalization were similar in PTCA and thrombolytic groups. Survival at 1-year follow-up was 88% in the PTCA group and 91% in the thrombolytic group (p = NS), and survival free of reinfarction was 85% and 88%, respectively (p = NS).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8023773     DOI: 10.1016/0002-9149(94)90082-5

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  7 in total

1.  Time to Reperfusion: The Critical Modulator in Thrombolysis and Primary Angioplasty.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1996       Impact factor: 2.300

2.  Current and Practical Management of Acute Myocardial Infarction.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997       Impact factor: 2.300

3.  Time to Treatment: A Crucial Factor in Thrombolysis and Primary Angioplasty.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1996       Impact factor: 2.300

4.  Spectrum of reperfusion strategies and factors influencing the use of primary angioplasty in patients with acute myocardial infarction admitted to hospitals with the facilities to perform primary angioplasty. Maximal Individual Therapy in Acute Myocardial Infarction (MITRA) Study Group.

Authors:  R Zahn; R Schiele; K Seidl; K E Hauptmann; T Voigtländer; H J Rupprecht; M Gottwik; H G Glunz; J Senges
Journal:  Heart       Date:  1999-10       Impact factor: 5.994

5.  Time as an Adjunctive Agent to Thrombolytic Therapy.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1994       Impact factor: 2.300

6.  Door-to-Balloon Delays with PCI in Acute Myocardial Infarction.

Authors:  Daniel R. Guerra; C. Michael Gibson
Journal:  Curr Treat Options Cardiovasc Med       Date:  2004-02

7.  Altered serum creatine kinase level and cardiac function in ischemia-reperfusion injury during percutaneous coronary intervention.

Authors:  Yi Luo; Yi-Zhi Pan; Chong Zeng; Guang-lian Li; Xiao-ming Lei; Zhen Liu; Shu-Feng Zhou
Journal:  Med Sci Monit       Date:  2011-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.